Talal Khairi, MD
Nephrology · Glendale, WINPI 1043471436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Amgen at 27.7% of the total. Reporting peaked in 2023 at $2,014 and has fallen 69.6% since, to $613 in 2025.
Across 261 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Bayer$546
- AstraZeneca$489
- Calliditas Therapeutics US Inc.$363
- GSK$331
- Vifor Pharma, Inc.$308
- plus $3K from 22 others
What the payments were for
- Food & beverage$5,99994%
- Education$3636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 61 | $1,761 |
| Bayer | 21 | $546 |
| AstraZeneca(2 entities) | 19 | $489 |
| Calliditas Therapeutics US Inc. | 13 | $363 |
| GSK | 16 | $331 |
| Vifor Pharma, Inc. | 19 | $308 |
| Boehringer Ingelheim | 12 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $293 |
| Mallinckrodt Hospital Products Inc. | 12 | $261 |
| Novartis | 9 | $214 |
| OPKO Pharmaceuticals, LLC | 12 | $207 |
| Travere Therapeutics, Inc. | 10 | $162 |
| Baxter Healthcare | 1 | $147 |
| Aurinia Pharma U.S., Inc. | 4 | $115 |
| Ardelyx, Inc. | 5 | $108 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $104 |
| ANI Pharmaceuticals, Inc. | 4 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $88 |
| Fresenius USA Marketing, Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Akebia Therapeutics Inc | 3 | $72 |
| Ultragenyx Pharmaceutical Inc. | 3 | $54 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Lilly USA, LLC | 2 | $49 |
| Novo Nordisk | 2 | $36 |
| Sanofi | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,362 in reported general payments places this provider in the 85th percentile of 173 nephrology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tolvaptan | 13 | $88,200 |
| JardianceEmpagliflozin | 70 | $86,478 |
| KerendiaFinerenone | 12 | $16,871 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $14,603 |
| FarxigaDapagliflozin Propanediol | 15 | $14,593 |
| Cinacalcet Hcl | 17 | $13,076 |
| Bumetanide | 155 | $4,550 |
| Sevelamer Carbonate | 40 | $4,450 |
| Midodrine Hcl | 43 | $3,172 |
| ProsolParenteral Amino Acid 20% No.1 | 33 | $3,148 |
| Calcium Acetate | 28 | $2,655 |
| Febuxostat | 19 | $2,409 |
| Potassium Citrate ErPotassium Citrate | 13 | $2,260 |
| Potassium Chloride | 51 | $1,413 |
| Losartan Potassium | 115 | $1,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $104 | $88,20013 claims |
| Boehringer IngelheimJardiance | $303 | $86,47870 claims |
| AstraZenecaLokelma, Farxiga | $489 | $29,19629 claims |
| BayerKerendia | $546 | $16,87112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 173 nephrology providers in Wisconsin.
Other nephrology in Glendale
- Rishi KoraGlendale$57K
- Anushayanthan AlfredGlendale$8K
- Kamal AminGlendale$4K
- Lisa HallerGlendale$3K
- Stephen SieversGlendale$2K
- Kevin RegnerMilwaukee$246K
- Rosanna RanieriKenosha$84K
- Micah ChanFitchburg$80K
- Manohar AhujaMilwaukee$35K
- Ashraf El MeanawyMilwaukee$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.